<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="3. Figure 3 Some important diagnostic and therapeutic targets for" exact="SARS-CoV-2 infection." post="ACE2, angiotensin-converting enzyme 2; R, receptor; IL, interleukin; GCSF,"/>
 <result pre="of camostat in protecting mice from death from a lethal" exact="SARS-CoV infection" post="with a 60% survival rate (34). It is considered"/>
 <result pre="mg, three times) of camostat daily are expected to reduce" exact="SARS-CoV-2 infection;" post="but human clinical trials are needed (35). Mesylate camostat,"/>
 <result pre="of inflammation of the pancreas in Japan. Remdesivir Antiviral for" exact="Ebola" post="Inhibits RNA-dependent RNA polymerase, prematurely blocking RNA transcription. Broad"/>
 <result pre="in vivo studies; The safety profile has been demonstrated in" exact="Ebola" post="studies; Superior efficacy of the Lopinavir/Ritonavir/IFNbeta combination in animal"/>
 <result pre="longer (39). Reduced side effects Favipiravir Antiviral for flu and" exact="Ebola" post="RNA polymerase inhibitor Used in China in patients of"/>
 <result pre="cells by abrogating the infection, resulting in the inhibition of" exact="SARS-CoV-2 infection" post="and spread (44). Emergence of the HCoV strains such"/>
 <result pre="vitro and in vivo studies; a safety profile demonstrated in" exact="Ebola" post="studies; and a higher efficacy than the combination lopinavir/ritonavir/IFN"/>
 <result pre="RNA polymerase inhibitor that has been used for influenza and" exact="Ebola" post="infection. It was originally produced in Japan and used"/>
 <result pre="The convalescent plasma was also used during the 2013 African" exact="Ebola" post="epidemic (62). Experience from previous coronavirus situations, such as"/>
 <result pre="this year (72). The efficacy of nafamostat in patients with" exact="Covid-19" post="(RACONA study), is the subject of another ongoing clinical"/>
 <result pre="toxic (77). Recently, hydroxychloroquine was found to efficiently inhibit the" exact="SARS-CoV-2 infection" post="in vitro through an anti-inflammatory mechanism (48). In a"/>
 <result pre="several phase I and II studies, carried out within the" exact="SARS-CoV-2 infection." post="The therapeutic hypothesis is that the immunomodulatory and regenerative"/>
 <result pre="addressing public health emergencies, having been active during the 2014" exact="Ebola" post="outbreak (93, 94). China has already announced that it"/>
 <result pre="adenoviruses. It is the same platform where a vaccine for" exact="Ebola" post="was successful in 2017 (95). Ad5-nCoV is a novel"/>
 <result pre="several potential molecules; from remdesivir, an antiviral previously tested for" exact="Ebola" post="already approved by the FDA, to antiretrovirals used against"/>
 <result pre="remedies along with personal precautions are urgently needed to avoid" exact="SARS-CoV-2 infection." post="Author Contributions MT, MN, IK, SM, MK-E-Z, TA, and"/>
 <result pre="Wuhan, China. Int J Infect Dis. (2020) 91:264â€&quot;66. 10.1016/j.ijid.2020.01.00931953166 3.ChanJFLauSKToKKChengVCWooPCYuenKY." exact="Middle East respiratory syndrome" post="coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol"/>
 <result pre="10.1016/j.toxrep.2020.04.01232355638 13.GuoYRCaoQDHongZSTanYYChenSDJinHJet al.. The origin, transmission and clinical therapies on" exact="coronavirus disease 2019" post="(COVID-19) outbreak - an update on the status. Mil"/>
 <result pre="and epidemic predictions. medRxiv. (2020). 10.1101/2020.01.23.20018549 20.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of" exact="coronavirus disease 2019" post="in China. N Engl J Med. (2020) 382:1708â€&quot;20. 10.1056/NEJMoa200203232109013"/>
 <result pre="of clinical diagnosis and treatment of a case infected with" exact="coronavirus disease 2019." post="J Med Virol. (2020) 92:461â€&quot;3. 10.1002/jmv.2571132073161 24.DoceaAOGofitÄƒECalinaDZaharieSValceaDIMitru?PAutoimmune disorders due"/>
 <result pre="al.Case of the index patient who caused tertiary transmission of" exact="coronavirus disease 2019" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from" exact="Middle East respiratory syndrome" post="coronavirus. J Biol Chem. (2020) 295:4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 46.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet"/>
 <result pre="a less toxic derivative of chloroquine, is effective in inhibiting" exact="SARS-CoV-2 infection" post="in vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 49.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIet al.."/>
 <result pre="fusion assay. Antimicrob Agents Chemother. (2016) 60:6532â€&quot;9. 10.1128/AAC.01043-1627550352 50.BurkiTOutbreak of" exact="coronavirus disease 2019." post="Lancet Infect Dis. (2020) 20:292â€&quot;3. 10.1016/S1473-3099(20)30076-132078809 51.ZhouYHouYShenJHuangYMartinWChengF. Network-based drug"/>
 <result pre="69.collab: Oslo University HospitalThe Efficacy of Different Anti-viral Drugs in" exact="COVID 19" post="Infected Patients. NCT04321616 (2020). Available online at: https://clinicaltrials.gov/ (accessed"/>
 <result pre="April 10, 2020). 73.collab: University Hospital PadovaEfficacy of Nafamostat in" exact="Covid-19" post="Patients (RACONA Study) (RACONA). NCT04352400 (2020). Available online at:"/>
 <result pre="Mol Med Rep. (2017) 16:8771â€&quot;80. 10.3892/mmr.2017.774629039613 80.SandersJMMonogueMLJodlowskiTZCutrellJB. Pharmacologic treatments for" exact="coronavirus disease 2019" post="(COVID-19): a review. JAMA. (2020) 323:1824â€&quot;36. 10.1001/jama.2020.601932282022 81.ChenLXiongJBaoLShiY. Convalescent"/>
 <result pre="(2009) 7:226â€&quot;36. 10.1038/nrmicro209019198616 94.AgnandjiSTHuttnerAZinserMENjugunaPDahlkeCFernandesJFet al.. Phase 1 trials of rVSV" exact="Ebola" post="vaccine in Africa and Europe. N Engl J Med."/>
</results>
